NCT07379840
A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea
Recruiting · Not specified · Bayer · registry updated 2026-02-03
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is an observational study in which data from people with chronic heart failure (HF) with left ventricular ejection fraction (LVEF) ≥ 40%. who will be receiving finerenone are studied. The study is conducted to check the safety of finerenone after it is approved and available in South Korea. Observational studies use data that are collected as part of routine medical care and participants do not receive any advice or any changes to healthcare as part of the study. In this study, the data will be collected from participants who are receiving their usual treatment with finerenone as prescribed by their doctor according to the approved product information. Heart failure with LVEF ≥ 40% is a condition which occurs when the left side of the heart does not pump blood out to the body as well as it should. Over time, the body does not get the amount of oxygen it needs. This can lead to shortness of breath and tiredness, making it difficult for people to do their daily tasks. The study drug, finerenone, is already approved for doctors to prescribe to people with chronic heart failure. It works by blocking a specific receptor in the body called the mineralocorticoid receptor (MR)....
Inclusion
- Adults aged 19 years or older
- With informed consent from subject or legal representative (Prioritizing patient consent)
- Finerenone naïve patients who are prescribed finerenone for treatment of chronic HF with LVEF ≥40%
Exclusion
- Contraindication according to the local label (including known hypersensitivity to the drug substance or any of its components)
- Patients participating in an investigational program with interventions outside of routine clinical practice (NYHA classes II-IV) in accordance with local label